Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied. Cladribine is designed to interfere with the cell's ability to process DNA (the genetic material of cells). It can also insert itself into the DNA of cancer cells to stop them from growing and repairing themselves. Cytarabine is designed to insert itself into DNA of cancer cells to stop them from growing and repairing themselves. Decitabine is designed to damage the DNA of cells, which may cause cancer cells to die. This is an investigational study. Cladribine is FDA approved and commercially available for use in patients with hairy cell leukemia. Its use in patients with AML is investigational. Cytarabine is FDA approved and commercially available for use in patients with AML. Decitabine is FDA approved and commercially available for use in patients with MDS. Its use for patients with AML is investigational. Up to 160 patients will take part in this study. All will be enrolled at MD Anderson.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wcześniej nie leczona białaczka szpikowa (AML) lub zespół mielodysplastyczny wysokiego ryzyka
- •Wiek 60 lat lub więcej (lub poniżej 60 lat, jeśli pacjent nie może tolerować standardowego leczenia)
- •Sprawna funkcja wątroby i nerek
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Ujemny test ciążowy u kobiet w wieku rozrodczym
- •Świadoma zgoda na uczestnictwo w badaniu
- •Wcześniejsze leczenie decytabiną jest dopuszczalne, chyba że pacjent miał progresję choroby podczas tego leczenia
✗ Disqualifies
- •Ciąża lub okres karmienia piersią
- •Niekontrolowana infekcja, problemy z sercem lub niestabilny stan zdrowia
- •Alergia na składniki leków używanych w badaniu
- •Kobiety i mężczyźni w wieku rozrodczym bez właściwej ochrony antykoncepcyjnej
Simplified criteria — AI translation
Trial details
- Minimum age
- 60 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, United States
Trial contact
Tapan Kadia, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.